Forge Biologics, a cell and gene therapy-focused CDMO, used a series of communications this week to underscore its strategic role at the intersection of manufacturing, regulation, and sustainability. The company highlighted internal and external thought leadership, as well as a new third-party certification.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Forge spotlighted an internal discussion with Scientific and Medical Advisory Board member Maritza McIntyre, Ph.D., centered on how CDMOs can inform evolving gene therapy regulation. By sharing development-stage and operational insights with regulators, the company aims to help align innovation with what is technically feasible.
Management framed this regulatory engagement as part of de-risking development pathways and potentially shortening time to approval for clients. That positioning could make Forge more attractive to sponsors seeking partners experienced in navigating complex regulatory expectations for advanced therapies.
The company also emphasized comments from CEO John Maslowski in BioPharm International on manufacturing as a critical bottleneck in emerging therapeutic modalities. Maslowski cited challenges in standardization and scalability, reinforcing the need for new approaches to building and delivering complex biologics.
Rather than announcing specific contracts, Forge is using these discussions to present itself as a thought leader in high-value cell and gene therapy manufacturing. This visibility may support future business development with biotech and pharma clients that lack in-house capacity, particularly in a capacity-constrained market.
Separately, Forge reported it has achieved My Green Lab Certification across all laboratories and cGMP manufacturing suites, described as a global benchmark for lab sustainability. The effort is positioned as integral to operational excellence and environmental, health, and safety priorities.
The sustainability milestone may strengthen Forge’s appeal with ESG-focused investors and biopharma partners prioritizing greener supply chains. It could also contribute to long-term efficiency gains and enhance differentiation among peer CDMOs competing for global manufacturing mandates.
Taken together, the week’s updates portray Forge Biologics as investing in regulatory collaboration, manufacturing expertise, and sustainability infrastructure, moves that may bolster its competitive standing and support durable client relationships over time.